1. Home
  2. NGM

NGM

NGM Biopharmaceuticals Inc.

Logo NGM Biopharmaceuticals Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

0

NGM Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics based on scientific understanding of key biological pathways for the treatment of cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's products include, NGM313 (MK-3655), NGM120, NGM621, and NGM395 among others. These are focused on NASH, diabetes, oncology, AMD and metabolic disease.

Founded: N/A Country:
United States
United States
Employees: N/A City: SOUTH SAN FRANCISCO
Market Cap: 132.7M IPO Year: 2019
Target Price: $3.68 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.73 EPS Growth: N/A
52 Week Low/High: $0.60 - $4.69 Next Earning Date: 05-02-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: